[
  {
    "ts": "2026-01-07T04:36:04+00:00",
    "headline": "3 Healthcare Stocks with Exciting Potential",
    "summary": "Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 19.9% gain over the past six months, beating the S&P 500 by 9.1 percentage points.",
    "url": "https://finance.yahoo.com/news/3-healthcare-stocks-exciting-potential-043604111.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "4f5c8ad1-1d80-38c4-a757-ad4d994c7da0",
      "content": {
        "id": "4f5c8ad1-1d80-38c4-a757-ad4d994c7da0",
        "contentType": "STORY",
        "title": "3 Healthcare Stocks with Exciting Potential",
        "description": "",
        "summary": "Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 19.9% gain over the past six months, beating the S&P 500 by 9.1 percentage points.",
        "pubDate": "2026-01-07T04:36:04Z",
        "displayTime": "2026-01-07T04:36:04Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/621a415265c388bc8e9eb8ecaf0fb0a8",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "ABBV Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/K222hrzb0FJJlqrDZzsz7w--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/621a415265c388bc8e9eb8ecaf0fb0a8.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cD3IChyAhZhexmnMXW7jMA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/621a415265c388bc8e9eb8ecaf0fb0a8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/3-healthcare-stocks-exciting-potential-043604111.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-healthcare-stocks-exciting-potential-043604111.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "PODD"
            },
            {
              "symbol": "COR"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "ABT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T13:00:00+00:00",
    "headline": "AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call",
    "summary": "AbbVie (NYSE: ABBV) will announce its full-year and fourth-quarter 2025 financial results on Wednesday, February 4, 2026, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.",
    "url": "https://finance.yahoo.com/news/abbvie-host-full-fourth-quarter-130000465.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "afd76fdf-9592-3007-90c9-c26ad8d3ea32",
      "content": {
        "id": "afd76fdf-9592-3007-90c9-c26ad8d3ea32",
        "contentType": "STORY",
        "title": "AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call",
        "description": "",
        "summary": "AbbVie (NYSE: ABBV) will announce its full-year and fourth-quarter 2025 financial results on Wednesday, February 4, 2026, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.",
        "pubDate": "2026-01-07T13:00:00Z",
        "displayTime": "2026-01-07T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/dfc09b8ad6e963df1fc648eedb2e5816",
          "originalWidth": 16,
          "originalHeight": 16,
          "caption": "Cision",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rXE3NNd45oo.mG2YI_lDEA--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/dfc09b8ad6e963df1fc648eedb2e5816.cf.webp",
              "width": 16,
              "height": 16,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tAlhY3_GO4h74RxqryROyg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/dfc09b8ad6e963df1fc648eedb2e5816.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-host-full-fourth-quarter-130000465.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-host-full-fourth-quarter-130000465.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "META"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T14:00:04+00:00",
    "headline": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now",
    "summary": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.",
    "url": "https://finance.yahoo.com/news/why-investors-advantage-2-medical-140004056.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "6b1a9cf0-6618-3619-9b6f-ff97d18d6b21",
      "content": {
        "id": "6b1a9cf0-6618-3619-9b6f-ff97d18d6b21",
        "contentType": "STORY",
        "title": "Why Investors Need to Take Advantage of These 2 Medical Stocks Now",
        "description": "",
        "summary": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.",
        "pubDate": "2026-01-07T14:00:04Z",
        "displayTime": "2026-01-07T14:00:04Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/03fca48475577988aa4e0db94f484b4e",
          "originalWidth": 900,
          "originalHeight": 600,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9.bMA28djqdXWkJ0xgkrvA--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/03fca48475577988aa4e0db94f484b4e.cf.webp",
              "width": 900,
              "height": 600,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yGQaN1QLRXutAaqBqcTUKw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/03fca48475577988aa4e0db94f484b4e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-investors-advantage-2-medical-140004056.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-investors-advantage-2-medical-140004056.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T17:35:31+00:00",
    "headline": "What Retirees Need To Know About HDV’s Dividend Before Buying",
    "summary": "The iShares Core High Dividend ETF (NYSEARCA:HDV) offers retirees a 3.3% yield with 0.08% fees, tracking high-quality U.S. dividend payers. The fund generates income from dividends of blue-chip stocks concentrated in Consumer Staples (28%), Energy (24%), and Healthcare (17%). With $11.8 billion in assets and a 14-year track record, HDV appeals to income-focused investors. However, ... What Retirees Need To Know About HDV’s Dividend Before Buying",
    "url": "https://247wallst.com/investing/2026/01/07/what-retirees-need-to-know-about-hdvs-dividend-before-buying/",
    "source": "24/7 Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "17273e02-2063-34d3-b884-be1f9d3442ad",
      "content": {
        "id": "17273e02-2063-34d3-b884-be1f9d3442ad",
        "contentType": "STORY",
        "title": "What Retirees Need To Know About HDV’s Dividend Before Buying",
        "description": "",
        "summary": "The iShares Core High Dividend ETF (NYSEARCA:HDV) offers retirees a 3.3% yield with 0.08% fees, tracking high-quality U.S. dividend payers. The fund generates income from dividends of blue-chip stocks concentrated in Consumer Staples (28%), Energy (24%), and Healthcare (17%). With $11.8 billion in assets and a 14-year track record, HDV appeals to income-focused investors. However, ... What Retirees Need To Know About HDV’s Dividend Before Buying",
        "pubDate": "2026-01-07T17:35:31Z",
        "displayTime": "2026-01-07T17:35:31Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/24_7_wall_st__718/9d35b0f67d805b9bb69514eabd20b62d",
          "originalWidth": 768,
          "originalHeight": 1376,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Kj6STI89I_.37qwqegSnDg--~B/aD0xMzc2O3c9NzY4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/24_7_wall_st__718/9d35b0f67d805b9bb69514eabd20b62d.cf.webp",
              "width": 768,
              "height": 1376,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fyjWxY5UZDBwo2uUJ4T7Uw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/24_7_wall_st__718/9d35b0f67d805b9bb69514eabd20b62d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "24/7 Wall St.",
          "url": "https://247wallst.com/"
        },
        "canonicalUrl": {
          "url": "https://247wallst.com/investing/2026/01/07/what-retirees-need-to-know-about-hdvs-dividend-before-buying/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/retirees-know-hdv-dividend-buying-173531468.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "HDV"
            },
            {
              "symbol": "VHYAX"
            },
            {
              "symbol": "VYM"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T19:28:34+00:00",
    "headline": "AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.73",
    "summary": "AbbVie Inc. ( NYSE:ABBV ) will increase its dividend from last year's comparable payment on the 17th of February to...",
    "url": "https://finance.yahoo.com/news/abbvie-nyse-abbv-increasing-dividend-192834844.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "bd13c823-ac85-37a4-8af7-901c97a1183e",
      "content": {
        "id": "bd13c823-ac85-37a4-8af7-901c97a1183e",
        "contentType": "STORY",
        "title": "AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.73",
        "description": "",
        "summary": "AbbVie Inc. ( NYSE:ABBV ) will increase its dividend from last year's comparable payment on the 17th of February to...",
        "pubDate": "2026-01-07T19:28:34Z",
        "displayTime": "2026-01-07T19:28:34Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cbaG7tZ9A8mqrilci3AeIQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1OA9tdPdimVe1Dv1fa4MAQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-nyse-abbv-increasing-dividend-192834844.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-nyse-abbv-increasing-dividend-192834844.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T21:19:54+00:00",
    "headline": "AbbVie denies media reports of talks to buy Revolution Medicines",
    "summary": "By Puyaan Singh Jan 7 (Reuters) - AbbVie on Wednesday denied it was in talks to buy Revolution Medicines after the Wall Street Journal reported the drugmaker was in advanced discussions to acquire the",
    "url": "https://finance.yahoo.com/news/abbvie-talks-buy-biotech-revolution-200059398.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "5d357fb1-fe30-32ab-abb7-dfe5ede9cb7b",
      "content": {
        "id": "5d357fb1-fe30-32ab-abb7-dfe5ede9cb7b",
        "contentType": "STORY",
        "title": "AbbVie denies media reports of talks to buy Revolution Medicines",
        "description": "",
        "summary": "By Puyaan Singh Jan 7 (Reuters) - AbbVie on Wednesday denied it was in talks to buy Revolution Medicines after the Wall Street Journal reported the drugmaker was in advanced discussions to acquire the",
        "pubDate": "2026-01-07T21:19:54Z",
        "displayTime": "2026-01-07T21:19:54Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/18296b5c2a61f2a89accb5f92b78e3cd",
          "originalWidth": 800,
          "originalHeight": 533,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/y3CQ60AmUQdbSBBUORxtCA--~B/aD01MzM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/18296b5c2a61f2a89accb5f92b78e3cd.cf.webp",
              "width": 800,
              "height": 533,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/p.SPTiNZuzkzd6.C8xMKlw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/18296b5c2a61f2a89accb5f92b78e3cd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-talks-buy-biotech-revolution-200059398.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-talks-buy-biotech-revolution-200059398.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "RVMD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T20:47:07+00:00",
    "headline": "Sector Update: Health Care Stocks Gain Late Afternoon",
    "summary": "Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index adding 0.7% and th",
    "url": "https://finance.yahoo.com/news/sector-health-care-stocks-gain-204707424.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "70b57110-9ed2-3d9f-886a-6f8becadcc76",
      "content": {
        "id": "70b57110-9ed2-3d9f-886a-6f8becadcc76",
        "contentType": "STORY",
        "title": "Sector Update: Health Care Stocks Gain Late Afternoon",
        "description": "",
        "summary": "Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index adding 0.7% and th",
        "pubDate": "2026-01-07T20:47:07Z",
        "displayTime": "2026-01-07T20:47:07Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-gain-204707424.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-gain-204707424.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "VTYX"
            },
            {
              "symbol": "RVMD"
            },
            {
              "symbol": "XLV"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "VERA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T20:33:48+00:00",
    "headline": "Revolution Medicines stock surges over 20% on potential AbbVie acquisition",
    "summary": "Investing.com -- Revolution Medicines (NASDAQ:RVMD) stock surged 29% before trading was halted twice due to volatility following a Wall Street Journal report that AbbVie (NYSE:ABBV) is in advanced talks to acquire the clinical-stage precision oncology company.",
    "url": "https://finance.yahoo.com/news/revolution-medicines-stock-surges-over-203348157.html",
    "source": "Investing.com",
    "provider": "yfinance",
    "raw": {
      "id": "a69df173-9dee-393e-b513-3513d2c2eeef",
      "content": {
        "id": "a69df173-9dee-393e-b513-3513d2c2eeef",
        "contentType": "STORY",
        "title": "Revolution Medicines stock surges over 20% on potential AbbVie acquisition",
        "description": "",
        "summary": "Investing.com -- Revolution Medicines (NASDAQ:RVMD) stock surged 29% before trading was halted twice due to volatility following a Wall Street Journal report that AbbVie (NYSE:ABBV) is in advanced talks to acquire the clinical-stage precision oncology company.",
        "pubDate": "2026-01-07T20:33:48Z",
        "displayTime": "2026-01-07T20:33:48Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Investing.com",
          "url": "https://www.investing.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/revolution-medicines-stock-surges-over-203348157.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/revolution-medicines-stock-surges-over-203348157.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "RVMD"
            },
            {
              "symbol": "VSTM"
            },
            {
              "symbol": "TNGX"
            },
            {
              "symbol": "ERAS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T20:29:00+00:00",
    "headline": "AbbVie Near Deal for Revolution Medicines",
    "summary": "AbbVie  is in advanced talks to buy cancer-drug biotech  Revolution Medicines  according to people familiar with the matter, in what would be one of the year’s first megadeals.  Revolution Medicines had a market value of around $16 billion before The Wall Street Journal reported on the talks Wednesday afternoon.  Revolution had drawn interest from other suitors, some of the people said.",
    "url": "https://www.wsj.com/business/deals/abbvie-near-deal-for-revolution-medicines-eca830a1?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "f198437c-23e7-3227-9721-0809cfff3785",
      "content": {
        "id": "f198437c-23e7-3227-9721-0809cfff3785",
        "contentType": "STORY",
        "title": "AbbVie Near Deal for Revolution Medicines",
        "description": "",
        "summary": "AbbVie  is in advanced talks to buy cancer-drug biotech  Revolution Medicines  according to people familiar with the matter, in what would be one of the year’s first megadeals.  Revolution Medicines had a market value of around $16 billion before The Wall Street Journal reported on the talks Wednesday afternoon.  Revolution had drawn interest from other suitors, some of the people said.",
        "pubDate": "2026-01-07T20:29:00Z",
        "displayTime": "2026-01-07T20:29:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/f198437c-23e7-3227-9721-0809cfff3785/abbvie-near-deal-for.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/8629036cff961cc9c8e74bd5ed025167",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nf3zOaYcymq8Cfh5.26ZdA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/8629036cff961cc9c8e74bd5ed025167.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/594NgJkm8JTUzaC89g_oIw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/8629036cff961cc9c8e74bd5ed025167.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/business/deals/abbvie-near-deal-for-revolution-medicines-eca830a1?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "RVMD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T22:44:00+00:00",
    "headline": "Revolution Medicines Draws Takeover Interest",
    "summary": "AbbVie is in advanced talks to buy cancer-drug biotech Revolution Medicines, according to people familiar with the matter, in what would be one of the year’s first megadeals.  A deal could come together soon, granted the talks don’t hit any last-minute snags, the people said.  After The Wall Street Journal reported on the deal talks,  AbbVie  said it “is not in discussions” with Revolution.",
    "url": "https://www.wsj.com/business/deals/abbvie-near-deal-for-revolution-medicines-eca830a1?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "f198437c-23e7-3227-9721-0809cfff3785",
      "content": {
        "id": "f198437c-23e7-3227-9721-0809cfff3785",
        "contentType": "STORY",
        "title": "Revolution Medicines Draws Takeover Interest",
        "description": "",
        "summary": "AbbVie is in advanced talks to buy cancer-drug biotech Revolution Medicines, according to people familiar with the matter, in what would be one of the year’s first megadeals.  A deal could come together soon, granted the talks don’t hit any last-minute snags, the people said.  After The Wall Street Journal reported on the deal talks,  AbbVie  said it “is not in discussions” with Revolution.",
        "pubDate": "2026-01-07T22:44:00Z",
        "displayTime": "2026-01-07T22:44:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/f198437c-23e7-3227-9721-0809cfff3785/revolution-medicines-draws.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/8629036cff961cc9c8e74bd5ed025167",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nf3zOaYcymq8Cfh5.26ZdA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/8629036cff961cc9c8e74bd5ed025167.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/594NgJkm8JTUzaC89g_oIw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/8629036cff961cc9c8e74bd5ed025167.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/business/deals/abbvie-near-deal-for-revolution-medicines-eca830a1?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "RVMD"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T20:25:00+00:00",
    "headline": "Ironwood Pharmaceuticals’ 2026 Guidance Shock Sparks a Major Re-Rating",
    "summary": "Ironwood Pharmaceuticals rose 30% after a strategic price cut on Linzess unlocked higher revenue guidance and surprised Wall Street analysts.",
    "url": "https://www.marketbeat.com/originals/ironwood-pharmaceuticals-2026-guidance-shock-sparks-a-major-re-rating/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "dd16eed3-250c-3d65-94d0-cf79c2be37de",
      "content": {
        "id": "dd16eed3-250c-3d65-94d0-cf79c2be37de",
        "contentType": "STORY",
        "title": "Ironwood Pharmaceuticals’ 2026 Guidance Shock Sparks a Major Re-Rating",
        "description": "",
        "summary": "Ironwood Pharmaceuticals rose 30% after a strategic price cut on Linzess unlocked higher revenue guidance and surprised Wall Street analysts.",
        "pubDate": "2026-01-07T20:25:00Z",
        "displayTime": "2026-01-07T20:25:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/f99a5c00f643afbb14f83d085988c263",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "Ironwood logo appears in a green lab setting with plants and glassware, highlighting sustainable biotech research.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hXJ4.j16mRiV8bO881vXcQ--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/f99a5c00f643afbb14f83d085988c263.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_szcJXxWlYnU9J_a48MhPQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/f99a5c00f643afbb14f83d085988c263.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/originals/ironwood-pharmaceuticals-2026-guidance-shock-sparks-a-major-re-rating/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ironwood-pharmaceuticals-2026-guidance-shock-202500414.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "IRWD"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]